Background. In pre-hospital situations, delay in resuscitation might carry
Introduction
In pre-hospital situations, the feasibility of varied resuscitative management is crucial for patients and emergency medical technicians (EMTs). Out-of-hospital management should be rapid, easy-to use, and effective, even in rigorous situations. A prolonged stay at the scene might carry extra risks for patients. (1, 2) Intravenous, intraosseous, and administration via tracheal tube, are all practical methods for pre-hospital drug delivery. However, establishment of these routes is usually difficult and time-consuming in out-of-hospital situations. (3) (4) (5) These procedures prolong the length of stay and might be misplaced at the scene. (3, 5) A laryngeal mask airway (LMA) is an effective supraglottic airway device and is widely used by EMTs. A LMA can be placed quickly and easily by SIGNA VITAE 2016; 11(1): unfamiliar healthcare workers and the skill can be retained without frequent training. (6, 7) Furthermore, previous studies have revealed its potential to serve as a route for drug administration. (8) (9) (10) Vasopressin is a potent vasopressor with extended purposes in the treatment of severe trauma, septic shock, cardiac diseases and during cardiopulmonary resuscitation. (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) In addition, a few researchers have found that vasopressin is absorbed well via the mucosa of the airway and alveoli. (23) (24) (25) The combination of a LMA and vasopressin could be a practical management tool in pre-hospital settings.
Accordingly, we conducted this animal study to verify the feasibility of administering vasopressin via a LMA.
Materials and methods
The project was approved by the animal investigation committee of ChiMei Medical Center. The animals were managed in accordance with national and institutional guidelines. Sixteen female and 8 male Yorkshire pigs, with an average weight of 22.1 kg (range 16.5-25.7 kg; median 22.5 kg), were used in this study (table 1) . Before the experiment, the pigs were fasted overnight but given unrestricted access to water. The animals were premedicated with Tiletamine/Zolazepam (2.5 mg/kg) intramuscularly and were fixed in a dorsal recumbent position.
Anesthesia was inducted with 10 mg/kg pentothal injected into an ear vein. All of the pigs were able to breathe spontaneously without ventilator assistance and none of the animals needed an additional anesthetic agent to maintain anesthesia during the experiment. A femoral artery was catheterized for continuous arterial pressure and heart rate monitoring, and 3000U intravenous heparin was administered to avoid intra-catheter clot formation. The pigs were then randomly Company, Henley on Thames, UK) insertion. In the LMAC group, a catheter (MADett ® ; Wolfe Tory Medical, Salt Lake City, America) was placed into the trachea through the LMA to deliver the medication. The catheter was designed to aerosolize the injected solution, which facilitated the absorption of the drug. We used a fibrobronchoscopy to confirm the position of the tracheal tube, ensure that the opening of the larynx was faced directly towards the lower aperture of the LMA, and verify that the tip of the MADett ® catheter was located in the trachea.
After completing the above procedures, we allowed a 20-minute stabilization period to achieve a steady state.
Group Placebo: 5 ml of distilled water was administered via the tracheal tube.
Group TT: 1 U/Kg of vasopressin, diluted to a total volume of 5 ml with distilled water, was administered via the tracheal tube.
Group LMA: 1 U/Kg of vasopressin, diluted to a total volume of 5 ml with distilled water, was administered via the upper end of the LMA.
Group LMAC: 1 U/Kg of vasopressin, diluted to a total volume of 5 ml with distilled water, was administered via the MADett ® catheter.
Five forceful artificial ventilations were given via tracheal tube or LMA to help the spraying of medication after various drugs were administered.
The heart rate and arterial pressure were recorded before administration, at 30 seconds after drug administration, every minute for 9 minutes, and then every 2 minutes for 29 minutes. At the end of the experiment, the animals were killed using an injection of potassium chloride solution 10 mEq.
The results are presented as medians, unless otherwise stated.
Differences in heart rate and arterial pressure between the four groups were compared using the Kruskal-Wallis test, followed by the MannWhitney U test. Using the data before drug administration as the baseline, changes in hemodynamic variables were investigated using the SIGNA VITAE 2016; 11(1):
Friedman test followed by the Wilcoxon signed rank test. All statistical tests were performed using SPSS software package (SPSS 12.0), with a two-tailed significance level of 0.05.
Results
After drugs were administered via varied routes, the mean arterial pressure (MAP) and diastolic arterial pressure (DAP) of Group LMAC decreased significantly at 0.5 minutes and returned to baseline soon after, at 1 minute postinjection. Both MAP and DAP then increased significantly and maintained a plateau from 2 to 29 minutes. Similarly, Group TT showed a drop in MAP and DAP at 0.5 minutes and resumed baseline levels after vasopressin administration. Thereafter, the MAP and DAP elevated significantly from 3 to 7 minutes and the peak levels were higher than those of other groups. The DAP demonstrated no changes and the MAP demonstrated one occasional rise at 4 minutes in Group Placebo and at 7 minutes in Group LMA ( figure 1,2 ).
The heart rates in Group Placebo were higher than in other groups, but there were no statistically significant differences between Group Control and TT, or Group Placebo and LMA. Groups Placebo, TT and LMA showed no persistent changes in heart rate after vasopressin administration. In Group LMAC, the heart rate decreased significantly at 2 minutes after drug delivery and maintained a lower level until 29 minutes (figure 3).
Discussion
Vasopressin administered via tracheal tube elevated the MAP and DAP in the experimental animals, a finding that is in line with previous research. Animal studies demonstrate that vasopressin increases blood pressure and prevents hypovolemic cardiac arrest from fatal hemorrhage. (11, 12) In addition, to improve perfusion pressure of vital organs, exogenous administration of vasopressin provides the added benefit of enhancing clot formation. (13) Therefore, it seems reasonable to consider vasopressin for treating hemorrhagic shock patients at the scene.
In patients with septic shock, the development of relative vasopressin deficiency provides the rationale for using vasopressin as an adjunct to We found that vasopressin significantly reduces heart rate, and the bradycardiac effect could prevent the progression of tachycardia induced by cardiomyopathy. (32) Diastolic dysfunction is a major predictor of mortality in patients with septic shock and reduction of the heart rate in patients with diastolic dysfunction can achieve better ventricular filling. catheter; MAP, mean arterial pressure; TT, tracheal tube. **◆: The MAP is significantly higher than the baseline, p < 0.05 ***•: The MAP is significantly lower than the baseline, p < 0.05
Figure 2.
In Group TT and Group LMAC, the DAP decreased significantly at 0.5 minutes and returned to baseline soon after, at 1 minute after drug administration. The DAP then increased significantly and maintained a plateau from 3 to 7 minutes in Group TT and from 2 to 29 minutes in Group LMAC. The peak level of DAP in Group TT was higher than in other groups. In Group Placebo and Group LMA, the DAP demonstrated SIGNA VITAE 2016; 11(1): no significant differences from the baseline.
DAP, diastolic arterial pressure; LMA, laryngeal mask airway; LMAC, laryngeal mask airway and a catheter; TT, tracheal tube. **◆: The DAP is significantly higher than the baseline, p < 0.05 ***•: The DAP is significantly lower than the baseline, p < 0.05
Figure 3.
The heart rate after drug administration was highest in Group Placebo and lowest in Group LMAC. In Groups Placebo, TT and LMA, the heart rate showed no constant changes after drug delivery. In Group LMAC, the heart rate decreased significantly at 2 minutes after vasopressin administration and the bradycardiac effect was prolonged.
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